GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRadimed Corp (NAS:IRMD) » Definitions » Cash-to-Debt

iRadimed (iRadimed) Cash-to-Debt : 23.27 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is iRadimed Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. iRadimed's cash to debt ratio for the quarter that ended in Mar. 2024 was 23.27.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, iRadimed could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for iRadimed's Cash-to-Debt or its related term are showing as below:

IRMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 11.33   Med: 25.73   Max: No Debt
Current: 23.27

During the past 12 years, iRadimed's highest Cash to Debt Ratio was No Debt. The lowest was 11.33. And the median was 25.73.

IRMD's Cash-to-Debt is ranked better than
80.6% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.88 vs IRMD: 23.27

iRadimed Cash-to-Debt Historical Data

The historical data trend for iRadimed's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

iRadimed Cash-to-Debt Chart

iRadimed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.65 19.15 25.17 26.29 24.36

iRadimed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.23 20.38 21.78 24.36 23.27

Competitive Comparison of iRadimed's Cash-to-Debt

For the Medical Devices subindustry, iRadimed's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRadimed's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where iRadimed's Cash-to-Debt falls into.



iRadimed Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

iRadimed's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

iRadimed's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRadimed  (NAS:IRMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


iRadimed Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of iRadimed's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


iRadimed (iRadimed) Business Description

Traded in Other Exchanges
Address
1025 Willa Springs Drive, Winter Springs, FL, USA, 32708
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.
Executives
Roger E. Susi director, 10 percent owner, officer: CEO, President, Chairman C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
James B Hawkins director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Anthony Vuoto director
Monty K Allen director
Hilda Frederique Scharen-guivel director 440 PALM ISLAND SE, CLEARWATER BEACH FL 33767
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Christopher K. Scott officer: CHIEF FINANCIAL OFFICER & SECR C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Brent Johnson officer: Exec. VP. Sales & Marketing 4900 HOPYARD RD, SUITE 210, PLEASITAN CA 94588
Steven M. Nardi officer: VP MANUFACTURING C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Louis S. Waldman officer: CONTROLLER C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Leslie L Mcdonnell director, officer: Chief Exec Officer & Director 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Francis X. Casey officer: VP OF REG AND QUAL ASSURANCE C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
John K Mccreery officer: Chief Operating Officer IRADIMED CORP, 1025 WILLA SPRINGS BLVD, WINTER SPRINGS FL 32708
Jonathan Kennedy director INTERSIL CORPORATION, 1001 MURPHY RANCH ROAD, MILPITAS CA 95035
Serge Novovich director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708